Clinical evaluation of medicines for patients with mild cognitive impairment and mild dementia due to Alzheimer's disease in Japan
Abstract Lecanemab and donanemab were approved in Japan in September 2023 and September 2024, respectively, for the treatment of patients with mild cognitive impairment and mild dementia due to Alzheimer's disease. Evaluating the efficacy of these drugs requires demonstrating a clinically meani...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/trc2.70100 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|